Copley Acquisition Corp and Aditxt Agree to Take Ignite Proteomics Public via Business Combination Valuing Company at ~$150 Million
June 9, 2026
Copley Acquisition Corp and Ignite Proteomics (a wholly owned subsidiary of Aditxt) have entered into a definitive business combination agreement to take Ignite public. The transaction values Ignite at an implied equity value of approximately $150 million and is expected to create a newly formed holding company (Ignite Proteomics Holdings) with listings on the NYSE, with Ignite expected to become an independent public company following closing.
- Buyers
- Copley Acquisition Corp, Ignite Proteomics Holdings (newly formed public holding company)
- Targets
- Ignite Proteomics, LLC
- Sellers
- Aditxt, Inc.
- Industry
- Biotechnology
- Location
- Colorado, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
10x Genomics Acquires Proteintech Genomics to Expand Proteomics Capabilities
June 10, 2026
Biotechnology
10x Genomics announced it has acquired Proteintech Genomics, a division within Proteintech Group, to expand its proteomics capabilities for single-cell and spatial multiomics workflows on 10x platforms. The deal adds Proteintech Genomics’ Human Discovery Panel technology and supports 10x’s strategy of integrating transcriptomic and proteomic measurements, including capabilities planned for its Atera platform. Financial terms were not disclosed.
-
Aditxt Acquires Ignite Proteomics for $36 Million
March 19, 2026
Healthcare Services
Aditxt announced the $36 million acquisition of Ignite Proteomics, a commercial-stage precision oncology company. The deal was structured through the issuance of 36,000 shares of Aditxt’s newly designated Series A-2 convertible preferred stock, and Ignite will operate as a subsidiary within Aditxt’s oncology initiatives.
-
Aditxt Acquires Appili Therapeutics
October 10, 2024
Healthcare Services
Aditxt, Inc. announced that Appili Therapeutics shareholders will vote on a proposed acquisition of all issued and outstanding shares of Appili through a plan of arrangement. Appili’s board recommended shareholders vote in favor, and Aditxt intends to use Appili’s infectious disease pipeline (including the FDA-approved LIKMEZ) to expand its reach in combating life-threatening infections and biodefense threats.
-
Ignyte Acquisition Corp. Completes Business Combination with Peak Bio Co., Ltd.
November 2, 2022
Biotechnology
Ignyte Acquisition Corp. completed its business combination with clinical-stage biopharmaceutical company Peak Bio Co., Ltd. The combined company began trading on NASDAQ as “Peak Bio, Inc.” under ticker “PKBO.” The transaction followed stockholder approvals at Ignyte’s special meeting on October 25, 2022.
-
Ignite International Brands Proposed Going-Private via Share Consolidation
July 19, 2022
Consumer Products
Ignite International Brands, Ltd. announced its board-approved proposed going-private transaction through consolidating its outstanding subordinate voting shares on a 1-for-100,000 basis. Subject to shareholder and regulatory approvals, existing shareholders will be cashed out at Cdn $0.62 per cancelled share, and Ignite plans to delist from the Canadian Securities Exchange and cease reporting as a reporting issuer.
-
Cepton Technologies Completes Business Combination with Growth Capital Acquisition Corp.
February 10, 2022
Automotive
Cepton Technologies and Growth Capital Acquisition Corp. completed their previously announced business combination, with the combined company renamed Cepton, Inc. The deal takes Cepton public (Nasdaq: CPTN / CPTNW) to provide capital and support scaling of its lidar solutions for automotive ADAS, smart cities and industrial applications.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.